New Phase 2 Study for HBM9378/WIN378 Focuses on COPD Treatment

Harbour BioMed Initiates Phase 2 Study for COPD Treatment

Harbour BioMed, a leading global biopharmaceutical company, recently announced a major milestone in the treatment of chronic obstructive pulmonary disease (COPD). The company, listed on the Hong Kong Stock Exchange, revealed that the first patients have been dosed in the Phase 2 SIRIUS study of HBM9378/WIN378 (also known as SKB378). This trial aims to explore the efficacy of this novel fully human ultra-long-acting anti-TSLP antibody in patients suffering from COPD.

Understanding COPD

Chronic obstructive pulmonary disease is a progressive condition affecting millions around the globe. It is characterized by persistent respiratory difficulties, exacerbated by ongoing inflammation in the lungs. As the disease advances, patients often face increased hospital visits and a significant decline in lung function. Despite the availability of various inhaled treatments, a substantial number of patients, particularly those with moderate to severe COPD, still experience frequent exacerbations, which demonstrate the pressing need for innovative therapeutic solutions.

The SIRIUS Study

The SIRIUS study is a pivotal Phase 2 clinical trial that utilizes a randomized, double-blind, placebo-controlled, dose-finding approach. The study is specifically designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9378/WIN378 in individuals diagnosed with moderate to severe COPD. This in-depth investigation comes at a critical time as healthcare professionals seek to improve options for patients encountering debilitating symptoms of this illness.

According to Dr. Jingsong Wang, Founder and CEO of Harbour BioMed, the initiation of the SIRIUS study is a promising step toward advancing the clinical development of HBM9378/WIN378. He emphasized the significance of the molecule, highlighting its potential as a unique ultra-long-acting anti-TSLP antibody tailored for treating immunological disorders.

HBM9378/WIN378 Overview

HBM9378/WIN378 is engineered to block the TSLP ligand, a crucial player in various immunological disease pathways, including asthma and COPD. The unique properties of this monoclonal antibody allow for extended half-life, making it suitable for biannual dosing. Previous Phase 1 trials have demonstrated its safety and tolerability at high doses, with a low incidence of anti-drug antibodies, which bodes well for its future development.

The Phase 2 data from the SIRIUS study is anticipated to complement ongoing research, including the Phase 2/3 POLARIS asthma study, with initial readouts expected later in 2026. Furthermore, the commencement of the first Phase 3 trial for HBM9378/WIN378 geared toward asthma treatment is projected to launch in Q4 2026.

Industry Implications

With COPD being the third leading cause of mortality worldwide, the development of effective treatments is crucial. The promising findings from the SIRIUS study could provide new hope for the millions grappling with this condition. Windward Bio, Harbour BioMed’s partner in this endeavor, is committed to advancing therapeutic methodologies for serious immunological issues. Their expertise in drug development plays a vital role in the future success of HBM9378/WIN378.

As Harbour BioMed continues to push the boundaries in biopharmaceutical innovation, the SIRIUS study stands as a testament to their dedication to addressing unmet medical needs. By focusing on conditions like COPD, they are actively working towards enhancing the quality of life for patients worldwide.

For more details about the study and Harbour BioMed's other groundbreaking initiatives, you can visit their official website or stay tuned for more updates as they progress through this crucial phase of research.